Asset
BATOCLIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03863080 | phase2 | completed | 2019-05-21 | 2020-10-07 | Immunovant Sciences GmbH | A Study of RVT-1401 in Myasthenia Gravis (MG) Patients |
| NCT03938545 | phase2 | terminated | 2019-07-23 | 2021-02-02 | Immunovant Sciences GmbH | ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) |
| NCT07188844 | phase2 | terminated | 2025-08-28 | 2026-07-16 | Immunovant Sciences GmbH | An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| NCT05517447 | phase3 | terminated | 2022-11-06 | 2026-04-02 | Immunovant Sciences GmbH | Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease |
| NCT05403541 | phase3 | terminated | 2022-06-27 | 2025-01-10 | Immunovant Sciences GmbH | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
FDA applications (0)
This company has no applications containing this asset.